- Home
- DRIO vs SLGL Comparison
DRIO vs SLGL Comparison
Compare DRIO & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- SLGL
- Stock Information
- Founded
- DRIO 2011
- SLGL 1997
- Country
- DRIO United States
- SLGL Israel
- Employees
- DRIO N/A
- SLGL N/A
- Industry
- DRIO Medical/Dental Instruments
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- SLGL Health Care
- Exchange
- DRIO Nasdaq
- SLGL Nasdaq
- Market Cap
- DRIO 28.3M
- SLGL 21.1M
- IPO Year
- DRIO N/A
- SLGL 2018
- Fundamental
- Price
- DRIO $0.72
- SLGL $7.21
- Analyst Decision
- DRIO Strong Buy
- SLGL Buy
- Analyst Count
- DRIO 2
- SLGL 1
- Target Price
- DRIO $2.50
- SLGL $40.00
- AVG Volume (30 Days)
- DRIO 157.7K
- SLGL 39.3K
- Earning Date
- DRIO 05-14-2025
- SLGL 05-23-2025
- Dividend Yield
- DRIO N/A
- SLGL N/A
- EPS Growth
- DRIO N/A
- SLGL N/A
- EPS
- DRIO N/A
- SLGL N/A
- Revenue
- DRIO $28,034,000.00
- SLGL $12,103,000.00
- Revenue This Year
- DRIO $16.54
- SLGL N/A
- Revenue Next Year
- DRIO $21.93
- SLGL $31.17
- P/E Ratio
- DRIO N/A
- SLGL N/A
- Revenue Growth
- DRIO 47.20
- SLGL 603.66
- 52 Week Low
- DRIO $0.50
- SLGL $3.34
- 52 Week High
- DRIO $1.57
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- DRIO 52.54
- SLGL 50.19
- Support Level
- DRIO $0.63
- SLGL $7.15
- Resistance Level
- DRIO $0.74
- SLGL $7.99
- Average True Range (ATR)
- DRIO 0.05
- SLGL 0.43
- MACD
- DRIO 0.00
- SLGL -0.13
- Stochastic Oscillator
- DRIO 56.73
- SLGL 27.59
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.